by Maureen Parkinson, Vocational Rehabilitation Counsellor and Dr. Christine Maheu, Nurse Scientist, McGill University, Co-Principal Investigators Cancer and Work
While 60 percent of those diagnosed with cancer will return to work one to two years following treatment, 25 to 53 percent will either quit or lose their jobs. These numbers are a clear indication that there has been a need for comprehensive information to support a return to work for many cancer survivors.
Photo Credit: Wikimedia Commons.
Summary by Dr. Luis Souhami MD – McGill University Health Centre
In our paper we critically reviewed major publications that evaluated the use of radiation therapy (RT) combined with androgen deprivation for localized prostate cancer. Also, a brief summary of some important preclinical studies was made in order to reinforce a better understanding of the biological basis for this approach. For didactic purposes, we have clustered prospective randomized trials in two major groups: one including studies basically testing hormonal therapy before RT (neoadjuvant therapy) and other using hormonal therapy concomitantly and/or after RT. Based on this scheme, we endeavoured to properly define most appropriate treatment recommendations for each risk category.